Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Headway Seen In EU-India FTA Talks, Commerce Ministry Joint Secretary Says

This article was originally published in PharmAsia News

Executive Summary

Disputes over EU blockades of Indian drug shipments are still on the negotiation table, says Commerce Ministry. India hopes to initiate talks with China as well.

You may also be interested in...

Chinese Government Takes First Steps To De-link Indigenous Innovation And Procurement, But Industry Groups Wary

SHANGHAI - Months after pledging a policy change, China is finally taking steps to break ties between indigenous innovation and government procurement policies. The changes in policy, according to a report released by the U.S.-China Business Council, address growing concern among multinationals that procurement policies - an estimated $1 trillion market - are increasingly designed to shut them out

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck

Indian Lobby Warns Of Proposed EU-India Free Trade Agreement's Impact; Says Drug Supplies Of Developing Nations May Be In Jeopardy

MUMBAI - As India and the European Union draw closer to signing a comprehensive Free Trade Agreement, the Indian Pharmaceutical Alliance - an influential lobby group of leading Indian pharmaceutical companies - has appealed to the Indian government to exercise caution and abstain from giving in to EU's demands, particularly those that allegedly ask for "TRIPS plus" provisions to be incorporated in the Indian legal framework

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts